Advertisement
Canada markets closed
  • S&P/TSX

    22,814.81
    +206.81 (+0.91%)
     
  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     
  • DOW

    40,589.34
    +654.24 (+1.64%)
     
  • CAD/USD

    0.7228
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    76.44
    -0.72 (-0.93%)
     
  • Bitcoin CAD

    94,299.91
    +83.33 (+0.09%)
     
  • CMC Crypto 200

    1,377.83
    +47.22 (+3.55%)
     
  • GOLD FUTURES

    2,385.70
    +4.70 (+0.20%)
     
  • RUSSELL 2000

    2,260.07
    +37.09 (+1.67%)
     
  • 10-Yr Bond

    4.2000
    -0.0560 (-1.32%)
     
  • NASDAQ

    17,357.88
    +176.18 (+1.03%)
     
  • VOLATILITY

    16.39
    -2.07 (-11.21%)
     
  • FTSE

    8,285.71
    +99.36 (+1.21%)
     
  • NIKKEI 225

    37,667.41
    -202.09 (-0.53%)
     
  • CAD/EUR

    0.6649
    -0.0018 (-0.27%)
     

AutoZone, Macy's rise; Unity Software, CarGurus fall, Tuesday, 2/27/2024

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes on Tuesday:

AutoZone Inc., up $184.53 to $2,954.99.

The auto parts retailer beat analysts' fiscal second-quarter earnings and revenue forecasts.

Macy's Inc., up 65 cents to $19.95.

The department store chain reported strong fourth-quarter financial results and announced plans to close 150 locations.

Zoom Video Communications Inc., up $5.05 to $68.17.

The video-conferencing company's fourth-quarter earnings and revenue beat Wall Street forecasts.

Unity Software Inc., down $2.02 to $31.02.

The video gaming software company gave investors a weak revenue forecast.

ADVERTISEMENT

CarGurus Inc., down 37 cents to $23.52.

The online auto shopping platform gave investors a disappointing financial forecast.

Expedia Group Inc., up $1.29 to $136.24.

The online travel company announced a restructuring plan that includes job cuts.

Norwegian Cruise Line Holdings Ltd., up $3.16 to $19.09.

The cruise line gave investors an encouraging earnings forecast.

Viking Therapeutics Inc., up $46.57 to $85.05.

The biopharmaceutical company gave investors an encouraging update for a potential weight-loss drug.